Sona Nanotech Inc.

Equities

SONA

CA83541C1059

Medical Equipment, Supplies & Distribution

Market Closed - Canadian Securities Exchange 03:54:55 2024-04-29 pm EDT 5-day change 1st Jan Change
0.35 CAD 0.00% Intraday chart for Sona Nanotech Inc. -16.67% +45.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sona Nanotech Provides Interim Results of Dalhousie Study MT
Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study CI
Sona Nanotech Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024 CI
Sona Nanotech Inc. Appoints Dr. Carman Giacomantonio to its Advisory Board CI
Sona Nanotech Inc. Announces Filing of Provisional Patent Application CI
Sona Nanotech Inc. Reports Earnings Results for the Full Year Ended October 31, 2023 CI
Sona Nanotech Inc. Announces Retirement of Michael Gross from the Board of Directors CI
Sona Nanotech Inc. announced that it has received CAD 0.75 million in funding CI
Sona Nanotech Inc. announced that it has received CAD 0.75 million in funding CI
Sona Nanotech Inc. announced that it expects to receive CAD 0.75 million in funding CI
Sona Nanotech Inc. announced that it expects to receive CAD 0.75 million in funding CI
Sona Nanotech Inc. Provides Corporate Update on Operating Activities CI
Sona Nanotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 CI
Sona Nanotech Inc. Announces Innovative Research Initiative to Undertake with Giacomantonio Immuno-Oncology Research Group CI
Sona Nanotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023 CI
Sona Nanotech Inc. Announces First Territorial Patent Grant for Its Proprietary, Toxin-Free Gold Nanorod Manufacturing Process with A Registration in South Korea CI
Sona Nanotech Inc. Announces Board Changes CI
Sona Nanotech Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023 CI
Sona Nanotech Inc. completed the acquisition of Siva Therapeutics Inc. CI
Sona Nanotech Inc. Auditor Raises 'Going Concern' Doubt CI
Sona Nanotech Inc. Reports Earnings Results for the Full Year Ended October 31, 2022 CI
Sona Nanotech Inc. completed the acquisition of Siva Therapeutics, Inc. CI
Sona Nanotech Inc. announced that it has received CAD 1.1 million in funding CI
Sona Nanotech Inc. Receives Technology Assessment Results from NCL CI
Sona Nanotech Inc. entered into a binding agreement to acquire Siva Therapeutics Inc. for $8.7 million. CI
Chart Sona Nanotech Inc.
More charts
Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.
More about the company
  1. Stock Market
  2. Equities
  3. SONA Stock
  4. News Sona Nanotech Inc.
  5. Sona Nanotech Provides Interim Results of Dalhousie Study